Shmuel Shoham

Medicine & Life Sciences

1. Coronavirus 100%
2. Infections 83%
3. Transplant Recipients 73%
4. SARS Virus 63%
5. Transplants 61%
6. Mycoses 49%
7. Invasive Fungal Infections 47%
8. Severe Acute Respiratory Syndrome 43%
9. Immunocompromised Host 40%
10. Cryptococcus neoformans 39%
11. Therapeutics 39%
12. Voriconazole 35%
13. Invasive Candidiasis 34%
14. Pandemics 33%
15. Multicenter Studies 31%
16. Fungi 31%
17. Antibodies 30%
18. Caspofungin 28%
19. Human Influenza 25%
20. Mortality 25%
21. Micafungin 25%
22. Communicable Diseases 24%
23. Vaccines 24%
24. Antiviral Agents 23%
25. Candida 23%
26. Aspergillosis 22%
27. Epidemiology 21%
28. Antibody Formation 21%
29. Candidemia 20%
30. Lung 20%
31. Intensive Care Units 19%
32. Tissue Donors 19%
33. Hematologic Neoplasms 19%
34. Zygomycosis 17%
35. Neutralizing Antibodies 17%
36. Clinical Trials 17%
37. isavuconazole 17%
38. Cockatoos 16%
39. Population 16%
40. Herpes Zoster Vaccine 15%
41. Guidelines 15%
42. Outpatients 15%
43. Pharmacokinetics 15%
44. Inpatients 15%
45. Immunosuppressive Agents 15%
46. Chickenpox Vaccine 15%
47. Microbiology 14%
48. Safety 13%
49. Aspergillus 13%